Amgen Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Amgen Inc. stock analysis AMGN overview
Somewhat Bullish +50

/C O R R E C T I O N -- Amgen/ - PR Newswire

📅 This correction notice updates the April 30, 2026 press release regarding Amgen's first quarter 2026 financial results previously issued via PR Newswire.

📈 CEO Robert A. Bradway stated that Q1 2026 results demonstrate business strength with 16 brands achieving double-digit growth despite patent expirations and increased competition.

💊 The company highlighted its robust pipeline, noting confidence in delivering long-term growth as a new wave of molecules progresses to Phase 3 clinical development.

📉 Non-GAAP financial measures, including free cash flow, were presented alongside GAAP figures with reconciliations available in the attached documentation.

💰 Biosimilars sales totaled $185 million in Q1 2026, up from $171 million in the same period of the prior year.

🔬 Ultra-Rare products include PROCYSBI®, RAVICTI®, ACTIMMUNE®, BUPHENYL®, and QUINSAIR® as categorized in the financial breakdown.

🌍 Product sales details are broken down by specific product and geographic region in the full report released on PR Newswire.

📊 Operating expense analysis covers Research & Development, Selling, General & Administrative costs, total operating expenses, and operating income percentage of product sales.

💧 Cash flow and balance sheet data are presented in billions except for share counts which are provided in millions.

🚀 Key pipeline updates include MariTide (maridebart cafraglutide), BLINCYTO (blinatumomab), IMDELLTRA (tarlatamab), and Xaluritamig (AMG 509).

🤝 Collaboration highlights include TEZSPIRE development with AstraZeneca, AMG 104 research with AstraZeneca, and Xaluritamig pursuant to a collaboration with Xencor.

🧬 Investigational assets listed include YL201 by MediLink, Zocilurtatug pelitecan by Zai Lab Limited, and Etakafusp alfa by Asher Biotherapeutics.

⚠️ Third-party trademarks for Opdivo (Bristol-Myers Squibb), Keytruda (Merck & Co.), and Ocrevus (Genentech) are noted as not belonging to Amgen.

🏢 Amgen maintains its headquarters in Thousand Oaks, California, where it has been a leader in biotechnology innovation for over 45 years.

🧬 The company uses technology and human genetic data to advance medicines treating cancer, inflammatory conditions, rare diseases, heart disease, and obesity.

🏆 Amgen is consistently recognized for innovation and workplace culture, receiving honors from Fast Company and Forbes.

📉 It remains one of the 30 companies comprising the Dow Jones Industrial Average® and continues to operate at the cutting edge of innovation.

Bullish Signals
  • Amgen's first quarter results demonstrate business strength with 16 brands achieving double-digit growth, enabling the company to navigate patent expirations and increased competition.
  • CEO Robert A. Bradway expressed confidence in delivering attractive long-term growth, supported by a new wave of molecules progressing in Phase 3 clinical development.
  • Ultra-Rare products segment shows robust performance with IMDELLTRA/IMDYLLTRA experiencing a change in sales exceeding 100%.
  • The company continues to advance its broad and deep pipeline targeting cancer, inflammatory conditions, rare diseases, heart disease, and obesity-related conditions.
  • Amgen maintains its position as one of the 30 companies comprising the Dow Jones Industrial Average®, highlighting its market stature.
Risk Factors
  • The company acknowledges significant business challenges, noting that growth in 16 brands is occurring while contending with 'expected patent expirations and increased competition,' indicating future revenue headwinds.
  • Biosimilar sales declined from $185 million in Q1 2026 to $171 million in Q1 2025, highlighting competitive pressure on legacy revenue streams.
  • Rare Disease business reported a loss of ($3) million in Q1 2026 compared to a nominal ($1) million loss in the prior year, signaling potential profitability struggles in this therapeutic area.
  • Management reliance on non-GAAP financial measures and adjustments for acquisitions, restructuring, and other items obscures the true GAAP performance and may mask underlying deterioration or one-time costs.
  • The company's future guidance and analysis depend heavily on 'expected patent expirations,' suggesting a known timeline of revenue cliff risks that are not being mitigated fast enough.
Full Analysis
On April 30, 2026, Amgen (NASDAQ: AMGN) released corrected financial results for the first quarter of 2026, following an initial notice regarding changes to a previous announcement from Thousand Oaks, California. CEO Robert A. Bradway highlighted that the company's 16 brands achieved double-digit growth during the period, reinforcing the strength of their business despite expected patent expirations and rising competition. The leadership expressed confidence in delivering long-term growth driven by a new wave of molecules advancing into Phase 3 clinical development. In terms of financial metrics, the report detailed product sales broken down by specific therapeutic areas such as Ultra-Rare products—which include PROCYSBI®, RAVICTI®, ACTIMMUNE®, BUPHENYL®, and QUINSAIR®—and other products like Aimovig® and EPOGEN®. Notably, biosimilars generated $185 million in sales for Q1 2026 compared to $171 million in the same quarter of the previous year (Q1 '25). The company also provided analysis on research and development expenses, selling, general, and administrative costs, as well as cash flow and balance sheet positions using both GAAP and non-GAAP financial measures. Free cash flow was computed by subtracting capital expenditures from operating cash flow in accordance with US Generally Accepted Accounting Principles (GAAP). Beyond quarterly results, Amgen provided updates on its extensive pipeline, including MariTide (maridebart cafraglutide), BLINCYTO, IMDELLTRA, and Xaluritamig (formerly AMG 509). Several assets are being developed in collaboration with other major pharmaceutical entities: TEZSPIRE is being co-developed with AstraZeneca, AMG 104 also with AstraZeneca, and Xaluritamig pursuant to a research collaboration with Xencor, Inc. The company further outlined its status on various investigational antibody-drug conjugates from partners MediLink and Zai Lab Limited, as well as Etakafusp alfa from Asher Biotherapeutics. The release concluded by reaffirming Amgen's position as an innovator advancing medicines to treat cancer, inflammatory conditions, rare diseases, heart disease, and obesity-related conditions, with CEO Bradway noting the company's presence in the Dow Jones Industrial Average®.